论文部分内容阅读
目的观察洛铂(LBP)对体外培养人卵巢癌细胞增殖的抑制作用。方法选用7种人卵巢癌细胞株SK-OV-3、ES-2、OVCAR-8、3AO、SW626、A2780、OVCAR-3,以顺铂(DDP)、卡铂(CBP)为对照,评价LBP单药或联合紫杉醇(PTX)、多西他赛(TXT)对体外培养人卵巢癌细胞增殖的抑制作用及其联合用药效应。结果 LBP、DDP、CBP单药均可明显抑制体外培养人卵巢癌细胞增殖,IC50分别为1.5~13.8、0.9~8.1和14.6~145.7μmol·L-1。LBP、DDP、CBP联合PTX、TXT的效应具有细胞特异性,其中,LBP联合TXT在SK-OV-3、OVCAR-8细胞中显示相加效应。结论 LBP单药具有明确的体外抗人卵巢癌细胞增殖活性,其活性与DDP相当,强于CBP;LBP联合TXT对卵巢癌细胞有可能产生相加的抗肿瘤作用,但有细胞特异性。
Objective To observe the inhibitory effect of lobaplatin (LBP) on the proliferation of human ovarian cancer cells in vitro. Methods Seven human ovarian cancer cell lines, SK-OV-3, ES-2, OVCAR-8, 3AAO, SW626, A2780 and OVCAR-3, were used as control. Monotherapy or combined with paclitaxel (PTX), docetaxel (TXT) on human ovarian cancer cell proliferation in vitro and its combined effect. Results LBP, DDP and CBP alone significantly inhibited the proliferation of human ovarian cancer cells with IC50 of 1.5-13.8, 0.9-8.1 and 14.6-145.7 μmol·L-1, respectively. The effects of LBP, DDP and CBP combined with PTX and TXT were cell-specific, and LBP combined with TXT showed additive effects in SK-OV-3 and OVCAR-8 cells. CONCLUSION: LBP alone has definite anti-human ovarian cancer cell proliferation activity in vitro, its activity is comparable to that of DDP, but stronger than that of CBP. LBP combined with TXT may have additive anti-tumor effect on ovarian cancer cells, but it has cell specificity.